In This Article:
The Australian market has shown mixed signals, with the ASX200 inching up by 0.2% while consumer sentiment continues to decline, reflecting a cautious economic outlook. In this environment, growth companies with significant insider ownership can be appealing as they often indicate confidence from those closest to the business's operations and strategy.
Top 10 Growth Companies With High Insider Ownership In Australia
| Name | Insider Ownership | Earnings Growth |
| SKS Technologies Group (ASX:SKS) | 29.7% | 24.8% |
| Emerald Resources (ASX:EMR) | 18.1% | 38.9% |
| Medallion Metals (ASX:MM8) | 13.8% | 67.5% |
| Acrux (ASX:ACR) | 20.2% | 91.8% |
| AVA Risk Group (ASX:AVA) | 15.7% | 77.3% |
| Pointerra (ASX:3DP) | 23.8% | 126.4% |
| Newfield Resources (ASX:NWF) | 31.5% | 72.1% |
| Plenti Group (ASX:PLT) | 12.8% | 120.1% |
| Brightstar Resources (ASX:BTR) | 16.2% | 84.5% |
| Findi (ASX:FND) | 34.8% | 112.9% |
We'll examine a selection from our screener results.
Mineral Resources
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Mineral Resources Limited operates as a mining services company with operations in Australia, Asia, and internationally, and has a market cap of A$6.84 billion.
Operations: The company's revenue is derived from several segments, including Energy (A$16 million), Lithium (A$1.41 billion), Iron Ore (A$2.58 billion), Mining Services (A$3.38 billion), and Other Commodities (A$19 million).
Insider Ownership: 11.7%
Mineral Resources is experiencing significant earnings growth, forecast at 40.6% annually, outpacing the Australian market's 12.5%. Despite trading at a substantial discount to its estimated fair value, profit margins have declined from 5.1% to 2.4%. Revenue growth is expected to be moderate at 6.4%, slightly above the market average of 5.9%. Recent leadership changes include Jenna Mazza transitioning roles and James McClements planning to step down as Chair by next year's AGM.
PolyNovo
Simply Wall St Growth Rating: ★★★★★☆
Overview: PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally with a market cap of A$1.40 billion.
Operations: The company's revenue segment focuses on the development, manufacturing, and commercialization of NovoSorb Technology, generating A$103.23 million.
Insider Ownership: 10.2%
PolyNovo Limited is poised for robust earnings growth, projected at 38.3% annually, significantly outpacing the Australian market's 12.5%. The company recently reported record monthly sales of A$10.1 million in November 2024, contributing to a year-to-date revenue increase of A$10.1 million compared to last year. Despite trading at a discount to its fair value estimate, PolyNovo's revenue growth forecast of 17.6% surpasses the market average but remains below high-growth thresholds.